Ngā hua rapu - Bader-Meunier, B

Safety of rituximab in children with auto-immune diseases mā Bader-Meunier, B, Quartier, P, Wouters, C

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Juvenile idiopathic arthritis with dry synovitis: clinical and imaging aspects in a cohort of 6 patients mā De Somer, L, Lambot, K, Wouters, C, Bader-Meunier, B

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

PReS-FINAL-2353: Are rasopathies new monogenic predisposing conditions to the development of systemic lupus erythematosus? mā Bader-Meunier, B, cave, H, jeremiah, N, Rieux-Laucat, F

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Pediatric systemic lupus erythematosus and human parvovirus B19 infection mā Bélien-Pallet, V, Sauvion, S, Salomon, R, Quartier, P, Bader-Meunier, B

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Diversity in clinical manifestations of autoinflammatory syndromes mā Boiu, S, Neven, B, Compeyrot-Lacassagne, S, Mouy, R, Bader-Meunier, B, Quartier, P

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Probable DRESS syndrome induced by IL-1 inhibitors mā Polivka, L., Diana, J. S., Soria, A., Bodemer, C., Quartier, P., Fraitag, S., Bader-Meunier, B.

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Is there any relationship between the exposure to mycophenolic acid and the clinical status in children with lupus? mā Jurado, C, Bader-Meunier, B, Ranchin, B, Decramer, S, Fischbac, M, Bérard, E, Saint-Marcoux, F

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Inflammatory arthritis associated with inflammatory bowel disease in children mā Desgranges, M, Ruemmele, FM, Duquesnes, A, Ginies, JL, Goulet, O, Quartier, P, Bader-Meunier, B

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Infantile Onset Panniculitis with Uveitis and Systemic Granulomatosis: immunohistochemical findings mā Wouters, CH, Quartier, P, Bader Meunier, B, Stichweh, D, Punaro, M, Martin, T, Roskams, T, Rose, CD

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Systemic-onset juvenile rheumatoid arthritis and ANCA-associated glomerulonephritis mā Belot, A, Bader-Meunier, B, Noel, LH, Prieur, AM, Niaudet, P, Salomon, R, Quartier, P

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

PW03-033 - SLC29A3 mutation: a new autoinflammatory condition mā Melki, I, Lambot, K, Jonard, L, Couloigner, V, Quartier, P, Neven, B, Bader-Meunier, B

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

PReS-FINAL-2133: Drug survival and switching of biological agents in systemic juvenile idiopathic arthritis mā Woerner, A, Uettwiller, F, Melki, I, Bader-Meunier, B, Mouy, R, Wouters, C, Quartier, P

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

P03-018 - Diversity in presenting manifestations of AUTOINFL mā Boiu, S, Neven, B, Compeyrot-Lacassagne, S, Mouy, R, Wouters, C, Bader-Meunier, B, Gattorno, M, Quartier, P

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

PReS-FINAL-2111: Cytomegalovirus, Epstein Barr virus and Varicella-Zoster virus infections in children with juvenile idiopathic arthritis treated with biologics mā Remy Piccolo, V, Sotou-Bere, S, Woerner, A, Mouy, R, Florkin, B, Bader-Meunier, B, Quartier, P

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

PReS-FINAL-2175: Pharmacokinetics of mycophenolate mofetil in children with lupus and clinical findings in favour of therapeutic drug monitoring mā Woillard, JB, Bader-Meunier, B, Salomon, R, Ranchin, B, Decramer, S, Fischbach, M, Berard, E, Saint-Marcoux, F

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Cytophagic histiocytic panniculitis: is it a macrophage activation syndrome in situ? mā Bader-Meunier, B, Fraitag, S, Janssen, CEI, de Saint Basile, G, Brochard, K, Brousse, N, Bodemer, C, Wouters, C

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Abdominal manifestations in childhood‐onset systemic lupus erythematosus mā Richer, O, Ulinski, T, Lemelle, I, Ranchin, B, Loirat, C, Piette, J C, Pillet, P, Quartier, P, Salomon, R, Bader‐Meunier, B

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

2.2 A phase II trial with canakinumab, a new IL-1beta blocking monoclonal antibody (ACZ885), to evaluate preliminary dosing, safety and efficacy profile in children with systemic J... mā Ruperto, N, Quartier, P, Wulffraat, N, Woo, P, Loy, A, Mouy, R, Bader-Meunier, B, Prakken, B, Noseda, E, Rordorf, C

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

14.2 Causes of early death in juvenile onset systemic lupus erythematosus (JSLE) mā Bader-Meunier, B, Klein, A, Aggarwal, A, Merino, R, Russo, R, Sztajnbok, F, Avcin, T, Knupp, S, Khubchandani, R, Ozen, S, Cimaz, R, Quartier, P

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa

Dosing patterns of canakinumab in patients with Cryopyrin-Associated Periodic Syndromes (CAPS): A comparative analysis of a study in Western versus Japanese patients mā Bader-Meunier, B, Hachulla, P, Kuemmerle-Deschner, J, Gattorno, M, Patel, N, Preiss, R, Lheritier, K, Imagawa, T, Nishikomori, R, Takada, H, Heike, T, Hara, T, Yokota, S

Whiwhi kuputuhi katoa Whiwhi kuputuhi katoa